Optimizing Cognitive Behavioral Interventions for Perinatal Depression
A wide range of delivery options may be effective for addressing symptoms of depression in perinatal individuals, and could therefore be leveraged to expand access to treatments.
Prediction of Postpartum Depression: Take a Closer Look at Question 3 on the PHQ-9
A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.
Using Metabolic Biomarkers to Predict Risk for Postpartum Depression
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
New Oral PPD Treatment Zuranolone Will Soon Hit the Market as Zurzuvae
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Update on Postpartum Depression Documentary: More Than Blue
We are looking to include two additional women who are early on in the postpartum period (under one year) and recovering from postpartum depression.
Zuranolone: A novel postpartum depression treatment, with lingering questions
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on August 15, 2023.
Using Predictive Modeling to Examine IV Ketamine and Esketamine for the Prevention of Postpartum Depression
Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
FDA Approves Zuranolone for the Treatment of Postpartum Depression
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
More Data on Zuranolone for Postpartum Depression: When Will It Hit the Market?
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
Post-Marketing Safety Data for Brexanolone (Zulresso)
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.